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Background: Gain-of-function mutations of tyrosine kinase FLT3 are frequently found in acute myeloid leukemia
(AML). This has made FLT3 an important marker for disease diagnosis and a highly attractive target for therapeutic
drug development. This study is intended to generate a sensitive substrate for assays of the FLT3 enzymatic activity.
Methods: We expressed in Escherichia coli cells a glutathione S-transferase (GST) fusion protein designated GST-
FLT3S, which contains a peptide sequence derived from an autophosphorylation site of FLT3. The protein was used
to analyze tyrosine kinase activity of baculovirus-expressed FLT3 and crude cell extracts of bone marrow cells from
AML patients. It was also employed to perform FLT3 kinase assays for FLT3 inhibitor screening.
Results: GST-FLT3S in solution or on beads was strongly phosphorylated by recombinant proteins carrying the
catalytic domain of wild type FLT3 and FLT3D835 mutants, with the latter exhibiting much higher activity and
efficiency. GST-FLT3S was also able to detect elevated tyrosine kinase activity in bone marrow cell extracts from
AML patients. A small-scale inhibitor screening led to identification of several potent inhibitors of wild type and
mutant forms of FLT3.
Conclusions: GST-FLT3S is a sensitive protein substrate for FLT3 assays. It may find applications in diagnosis of
diseases related to abnormal FLT3 activity and in inhibitor screening for drug development.
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FLT3 is a member of the class III receptor tyrosine kinase
(RTK) family. It is expressed in immature hematopoietic
cells and plays an important role in the normal develop-
ment of stem cells and the immune system [1,2]. Muta-
tions of FLT3 have been detected in approximately 30% of
patients with acute myelogenous leukemia (AML) and in
a small number of patients with acute lymphocytic
leukemia or myelodysplastic syndrome [3,4]. The most
common mutations of FLT3 found in hematopoietic ma-
lignancies involve internal tandem duplications (FLT3-
ITD) within the juxtamembrane domain, while point* Correspondence: Joe-zhao@ouhsc.edu
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reproduction in any medium, provided the ormutations within the tyrosine kinase domain (FLT3-TKD)
is found in about 7% of AML patients. Both types of
mutations cause constitutive activation of FLT3 kinase ac-
tivity, thereby turning on downstream signaling proteins
and resulting in uncontrolled cell proliferation [3-5].
FLT3 mutations are important markers for AML diag-
nosis, and FLT3-ITD is strongly associated with the poor
prognosis of AML patients [6]. In fact, detection of
FLT3-ITD is currently a routine diagnostic practice, and
the presence of FLT3-ITD guides therapeutic decisions
in AML patients with a normal karyotype [7,8]. As gain-
of-function mutants, FLT3-ITD and FLT3-TKD are obvi-
ous targets for therapeutic kinase inhibitors. Indeed,
inhibiting FLT3 tyrosine kinase activity has been the
focus of both preclinical and clinical research in AML.
Many potent FLT3 inhibitors have been identified, and
some have been clinically tested as single agents and in
combination with chemotherapy, but thus far clinicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an inhibitor of tyrosine protein kinases (VEGFR and
PDGFR) and Raf kinases, is the only approved FLT3 in-
hibitor for clinical use. Sorafenib is available for off-label
use although it does not usually lead to a complete re-
sponse [11]. Further effort in FLT3 inhibitor screening is
clearly needed. For this purpose, more effective methods
for FLT3 kinase activity assays are highly desirable.
In this study, we have generated a glutathione S-
transferase (GST) fusion protein carrying a peptide se-
quence derived from an autophosphorylation site of
human FLT3. This protein designated GST-FLT3S, can be
effectively phosphorylated by recombinant FLT3 enzymes.
It can be used to detect elevated FLT3 activity in bone
marrow cells from AML patients and to test inhibitory
effects of various protein kinase inhibitors. We believe
GST-FLT3S should find broad applications in detecting
increased FLT3 activity from clinical samples for diagnos-
tic purposes and for identifying effective FLT3 inhibitors
through small-scale testing and large-scale screening.
Results and discussion
GST-FLT3S is a highly effective substrate for assays of
FLT3 activity
We constructed a pGex-GST-FLT3S plasmid, which
encodes a GST fusion protein carrying the peptide se-
quence derived from the autophosphorylation site 589 of
FLT3. When induced by 1 mM isopropy1 β-D-1-thioga-
lactopyranoside, E. coli cells transformed by the plasmid
gave rise to a robust expression of GST-FLT3S in the ex-
clusion body. From 1 liter of cell culture, over 50 mg of
nearly homogeneous recombinant protein could usually
be obtained by using a single glutathione-Sepharose col-
umn. For FLT3 kinase activity assays, we first expressed
the catalytic domain of wild type and mutant forms of
FLT3 as 6xHis-tagged recombinant proteins by using the
baculovirus expression system. The recombinant proteins
were purified from extracts of infected Sf9 cells through
Ni-NTA-agarose columns. Figure 1 illustrates the results
of FLT3 kinase activity assays. GST-FLT3S was strongly
phosphorylated by recombinant proteins containing the
catalytic domain of wild type and D835H and D835Y mu-
tant forms of FLT3, while plain GST was not phosphory-
lated at all although it has 14 tyrosyl residues,
demonstrating the specificity of the FLT3 kinase and
phosphorylation of the FLT3 peptide fused to GST
(Figure 1A). It should be noted that the mutant forms dis-
played much stronger phosphorylation of GST-FLT3S
than wild type FLT3, although a lower amount of mutant
enzymes were used in the assays. When normalized to
protein expression level, FLT3D835Y and FLT3D835H
exhibited 15-fold higher specific activity (Figure 1B). We
further carried out reactions with different concentrations
of substrates. The phosphorylation of GST-FLT3S obeysMichaelis–Menten kinetics with Km values of 1.1, 0.32,
and 0.18 mg/ml GST-FLT3S for FLT3, FLT3D835H and
FLT3D835Y, respectively (Figure 1C). The data indicates
that the D835 mutants of FLT3 not only increase the cata-
lytic turnover but also use the substrate more efficiently at
lower concentrations. We further carried out the kinase
assays with GST-FLT3S immobilized on glutathione-
Sepharose beads and detected tyrosine phosphorylation
using a fluorescein-labeled antibody. The data demon-
strated consistent measurements of wild type and mutant
FLT3 kinase activity (Figure 1D). This also provides a
proof-of-principle for high throughput multiplex assays
with multiple substrates immobilized on beads.
GST-FLT3S can be used to detect increased tyrosine
kinase activity in AML samples
We employed GST-FLT3S to analyze cell extracts from
4 AML and 2 normal bone marrow samples. The assays
identified 2 AML samples (AML1 and 2) with significantly
increased phosphorylation of GST-FLT3S (p< 0.001,
Figure 2). Interestingly, none of the four AML samples
were found positive for the known FLT3-ITD and FLT3-
D835 mutations. The elevated GST-FLT3S phosphorylation
activity is likely caused by activation of FLT3 through other
unknown mutations or mechanisms. Of course, we cannot
rule out the involvement of other activated kinases which
may also phosphorylate GST-FLT3S. Sample AML-1, which
displayed over 6-fold increase in GST-FLT3S kinase activity,
is cytogenetically normal as found with AML3 and 4. Sam-
ple AML-2 with over 2-fold increase in GST-FLT3S kinase
activity was cytogenetically abnormal. GST-FLT3S thus
serves as a unique tool for analyses of abnormal FLT3 and
related kinase activities in patient samples. The assay
appeared to be highly sensitive because a cell extract with 4
μg of total proteins is sufficient for each analysis. We be-
lieve that GST-FLT3S may be used for diagnoses of AML
and other diseases involving elevated FLT3 activity. Further
studies with more patient samples are warranted.
FLT3 mutations have been found in many patients with
AML and ALL. Currently, various gene-based analyses
have been developed to detect such mutations, and this
has provided valuable information for diagnosis of the dis-
eases and has helped in designing proper treatments [5-7].
However, the gene-based assays reveal only the presence,
not the activity, of the mutant FLT3. Because GST-FLT3S
directly detects enzymatic activity, it should identify ab-
normal elevations of the FLT3 activity due to mutations of
the enzyme at unknown sites or to malfunction of other
signaling components that regulate FLT3.
GST-FLT3S can be used to screen FLT3 inhibitors
Protein kinase inhibitors have found major applications
in cancer therapies. With GST-FLT3S as a substrate, we
analyzed the inhibitory effects of several known protein
Figure 1 GST-FLT3S is an effective substrate for FLT3 kinase activity assays. Reactions were carried out with FLT3WT, FLT3D835Y, and
FLT3D835H at 1.6, 0.4, and 0.4 μg/ml, respectively. A. Assays performed in the presence of 0.2 mg/ml GST-FLT3S or GST. Tyrosine phosphorylation
was detected by using anti-phosphotyrosine antibody. Note that autophosphorylation of FLT3 was also seen. The protein levels of GST-FLT3S and
GST were revealed by Coomassie blue staining. B. Comparison of specific activity of wild type and two mutant forms of FLT3 recombinant
proteins determined with GST-FLT3S at 0.2 mg/ml. Error bars denote standard deviation. C. Activity assays performed with different
concentrations of GST-FLT3S. D. Activity assays performed with GST-FLT3S immobilized on glutathione-Sepharose beads. Fluorescent images were
acquired under fluorescent microscope with identical exposure times.
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tors included sunitinib, nilotinib, erlotinib, gefitinib, dasa-
tinib, imatinib, sorafenib, and lestaurtinib. Known targets
of these inhibitors are listed in Table 1. Except for lestaur-
tinib, all are FDA-approved anticancer drugs targeting
various tyrosine kinases. Data shown in Figure 3 demon-
strated that sunitinib, sorafenib, and lestaurtinib caused
over 90% inhibition of FLT3 activity at 0.3 μM while the
rest had essentially no effect. These results were expected
since these FLT3-inhibitory compounds are known to tar-
get multiple proteins kinases and have shown some effi-
cacy in clinical trials of AML with FLT3-ITD [12,13]. Our
study also demonstrated that these inhibitors target
FLT3D835H and FLT3D835Y equally well. Therefore,
GST-FLT3S could serve as a substrate for screening po-
tential FLT3 inhibitors.
Identifying potent inhibitors of oncogenic protein
kinases is a new trend in anticancer drug development
[9-11]. Our current study provides a unique protein sub-
strate for FLT3 kinase assays to test inhibitory effects of
existing protein kinase inhibitors and to screen chemical
libraries for new inhibitors. It is suitable for assays with
the substrate in solution or immobilized on a solid sur-
face, in small scale or in high throughput. It allowsdirect measurement of phosphorylation of added pro-
teins substrate with high sensitivity, serving as an alter-
native to inhibitor screening assays by determining
phosphorylation of synthetic peptide substrates, autop-
hopshorylation of kinases, and competition with ATP or
analogs for binding to kinases.
Conclusions
We have developed a robust protein substrate desig-
nated GST-FLT3S for assays of FLT3 kinase activity.
GST-FLT3S can be produced economically in large
quantities and used for assays of FLT3 in solution and
when immobilized on beads. It reveals activation of
FLT3 by mutations in the catalytic domain and detects
increased tyrosine kinase activities in the cell extracts
from AML patients. It can be used to test the effective-
ness of existing protein kinase inhibitors of FLT3 and for
large-scale inhibitor screening. We believe GST-FLT3S
should serve as an important tool for future studies
related to FLT3 and for disease diagnosis and thera-
peutic drug development. Finally, our study also demon-
strates that GST is an excellent carrier for expression of
short peptide sequences to serve as substrates of protein
kinases.
Figure 2 Bone marrow samples from AML patients possess
increased GST-FLT3S phosphorylation activities. A. White blood
cells from two normal and four AML bone marrow samples were
extracted. Kinase assays were performed with cell extracts at 0.2 mg/
ml in the presence of 0.2 mg/ml GST-FLT3S. Phosphorylation of
GST-FLT3S was detected by using anti-phosphotyrosine, and equal
protein loadings were revealed by anti-GAPDH (for house-keeping
protein glyceraldehyde 3-phosphate dehydrogenase) and Coomassie
blue staining (for GST-FLT3S). B. Quantitative representation of
GST-FLT3S phosphorylation activity. Error bars denote standard
deviation (n≥ 3).
Figure 3 Kinase assays with GST-FLT3S identify potent FLT3
inhibitors. A. Tyrosine kinase activity of wild type and mutation
forms of FLT3 were analyzed with 0.2 mg/ml GST-FLT3S in the
presence of indicated tyrosine kinase inhibitors at 0.3 μM.
Phosphorylation of GST-FLT3S was detected by using
anti-phosphotyrosine antibody. B. Quantitative representation of
GST-FLT3S phosphorylation activity. Error bars denote standard
deviation (n≥ 3). The stock solutions of inhibitors were made in
dimethyl sulfoxide (DMSO), which was used as control. Note the
strong inhibitory effects of sunitinib, sorafenib, and lestaurtinib.
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Materials and clinical samples
Monoclonal anti-phosphotyrosine antibody PY20 was
purchased from BD Biosciences. Protein kinase inhibi-
tors were from ChemieTek. De-identified normal and
AML bone marrow samples were collected from local
clinical laboratories. The samples were residues from
routine cytogenetic tests. Institutional review board ap-
proval was obtained before these samples were collected
and analyzed. The bone marrow samples were treated
with red cell lysis buffer, and proteins were extracted
from white cells with a whole-cell extraction bufferTable 1 Known targets of protein kinase inhibitors tested
Inhibitors Known Targets
Sunitinib VEGFRs, PDGFRs, KIT, and FLT3
Nilotinib BCR-ABL, KIT, DDRs, PDGFRs, and CSF-1R
Erlotinib EGFR and JAK2
Gefitinib EGFR, Her2, and Her3
Dasatinib BCR-ABL, SRCs, and KIT
Imatinib BCR-ABL, KIT, and PDGFRs
Lestaurtinib FLT3, JAK2, TrkA, TrkB, and TrkC
Sorafenib B-Raf, C-Raf, PDGFRs, VEGFRs, KIT, and FLT3containing 25 mM β-glycerophosphate (pH 7.3), 5 mM
EDTA, 2 mM EGTA, 5 mM β-mercaptoethanol, 1% Tri-
ton X-100, 0.1 M NaCl, 1 mM sodium vanadate, and a
protease inhibitor cocktail (Roche Applied Science). Cell
lysates were cleared by centrifugation in a microfuge at
13,000g, and clear extracts were used directly for FLT3
activity assays. The remaining pellets were used for
DNA isolation by using phenol/chloroform extraction
after digestion of proteins with proteinase K.
Expression and purification of GST-FLT3S and
recombinant FLT3
To make the GST-FLT3S construct, DNA oligos encod-
ing a peptide with the sequence SDNEYFYVD were
synthesized and ligated into the pGex-2T vector, follow-
ing a similar strategy previously described for a JAK2
substrate [14]. The peptide sequence was derived from
human FLT3 and contains the tyrosine 589 autopho-
sphorylation site. The recombinant fusion protein was
expressed in E. coli cells and then purified by using a
glutathione-Sepharose column. We employed the
baculovirus expression system to express various wild
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tyrosine kinases [15]. In brief, a DNA fragment encoding
the entire intracellular portion (amino acid residues
573–993) of human FLT3 was cloned into the pBlueba-
cHis2 vector (Invitrogen). D835H and D835Y and FLT3
kinase domain mutations were introduced by using site-
specific mutagenesis. The resultant plasmid DNAs, to-
gether with Bac-N-blue DNA, were used to transfect Sf9
insect cells to generate recombinant viruses according to
manufacturer’s protocol (Invitrogen). Recombinant pro-
teins were purified from cell extracts of baculovirus-
infected Sf9 cells by using Ni-NTA columns (Qiagen).Tyrosine kinase activity assays
Phosphorylation of GST-FLT3S by isolated tyrosine kinases
or cell extracts was carried out in a buffer system contain-
ing 25 mM Tris–HCl (pH 7.5), 10 mM MgCl2, 0.2 mM ad-
enosine 5’-triphosphate, and 2 mM dithiothreitol. Reactions
were usually run for 20 minutes at room temperature and
were stopped by SDS gel sample buffer. Tyrosine phosphor-
ylation of proteins was determined by immunoblotting
analyses with anti-phosphotyrosine antibody PY20, fol-
lowed by horseradish peroxidase-conjugated secondary
antibodies. Detection by the electrochemiluminescence
method, capture of immunoblot images, and quantification
of band signals were carried out by using FluorChem SP
imaging system from Alpha Innotech [14,15]. When the
activity assays were performed with GST-FLT3S bound to
glutathione-Sepharose beads, reactions were stopped by 15
mM EDTA, and tyrosine phosphorylation was detected by
using anti-phosphotyrosine antibody PY20 followed by a
fluorescein-conjugated secondary antibody. All microscopic
analysis was performed with an Olympus BX51 microscope
equipped with a DP71 camera.
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